Source link : https://www.newshealth.biz/health-news/dapirolizumab-cuts-disease-activity-steroid-use-in-sle/
WASHINGTON — The investigational anti-CD40 ligand agent dapirolizumab pegol (DZP) outperformed placebo in improving disease activity and reducing high-dose corticosteroid use in patients with systemic lupus erythematosus (SLE) in the phase 3 PHOENYCS GO trial. “We really think that dapirolizumab pegol may represent a novel treatment for lupus, particularly given its broad immune modulatory effects,” […]
Author : News Health
Publish date : 2024-11-25 08:46:39
Copyright for syndicated content belongs to the linked Source.